$67.88
1.13% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Verona Pharma plc Sponsored ADR Stock price

$67.12
+13.43 25.01% 1M
+39.95 147.04% 6M
+20.68 44.53% YTD
+49.21 274.76% 1Y
+61.50 1,094.31% 3Y
+60.89 977.37% 5Y
+53.62 397.19% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+3.60 5.67%
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Key metrics

Market capitalization $5.49b
Enterprise Value $5.38b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 947.32
P/S ratio (TTM) P/S ratio 966.99
P/B ratio (TTM) P/B ratio 42.09
Revenue growth (TTM) Revenue growth 1,131.31%
Revenue (TTM) Revenue $5.68m
EBIT (operating result TTM) EBIT $-156.03m
Free Cash Flow (TTM) Free Cash Flow $-104.25m
Cash position $336.04m
EPS (TTM) EPS $-1.94
P/E forward negative
P/S forward 137.65
EV/Sales forward 134.69
Short interest 9.93%
Show more

Is Verona Pharma plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy
100%

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5.68 5.68
1,135% 1,135%
100%
- Direct Costs 1.56 1.56
61% 61%
27%
4.12 4.12
908% 908%
73%
- Selling and Administrative Expenses 118 118
178% 178%
2,080%
- Research and Development Expense 41 41
104% 104%
722%
-155 -155
145% 145%
-2,729%
- Depreciation and Amortization 1.01 1.01
63% 63%
18%
EBIT (Operating Income) EBIT -156 -156
145% 145%
-2,747%
Net Profit -154 -154
203% 203%
-2,717%

In millions USD.

Don't miss a Thing! We will send you all news about Verona Pharma plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verona Pharma plc Sponsored ADR Stock News

Neutral
Seeking Alpha
about 21 hours ago
Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operat...
Neutral
GlobeNewsWire
one day ago
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
Neutral
GlobeNewsWire
10 days ago
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:
More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO David Zaccardelli
Employees 79
Founded 2005
Website www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today